RESUMEN
Severe Coronavirus Disease 2019 (COVID-19) is characterized by numerous complications, complex disease, and high mortality, making its treatment a top priority in the treatment of COVID-19. Integrated traditional Chinese medicine (TCM) and western medicine played an important role in the prevention, treatment, and rehabilitation of COVID-19 during the epidemic. However, currently there are no evidence-based guidelines for the integrated treatment of severe COVID-19 with TCM and western medicine. Therefore, it is important to develop an evidence-based guideline on the treatment of severe COVID-19 with integrated TCM and western medicine, in order to provide clinical guidance and decision basis for healthcare professionals, public health personnel, and scientific researchers involved in the diagnosis, treatment, and care of COVID-19 patients. We developed and completed the guideline by referring to the standardization process of the "WHO handbook for guideline development", the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Reporting Items for Practice Guidelines in Healthcare (RIGHT).
Asunto(s)
Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Medicamentos Herbarios Chinos/uso terapéutico , Infectología/tendencias , Medicina Tradicional China/tendencias , SARS-CoV-2/efectos de los fármacos , Antivirales/efectos adversos , COVID-19/diagnóstico , COVID-19/virología , Consenso , Técnica Delphi , Medicamentos Herbarios Chinos/efectos adversos , Medicina Basada en la Evidencia/tendencias , Interacciones Huésped-Patógeno , Humanos , Gravedad del Paciente , SARS-CoV-2/patogenicidad , Resultado del TratamientoRESUMEN
Dendrimers comprise a specific group of macromolecules, which combine structural properties of both single molecules and long expanded polymers. The three-dimensional form of dendrimers and the extensive possibilities for use of additional substrates for their construction creates a multivalent potential and a wide possibility for medical, diagnostic and environmental purposes. Depending on their composition and structure, dendrimers have been of interest in many fields of science, ranging from chemistry, biotechnology to biochemical applications. These compounds have found wide application from the production of catalysts for their use as antibacterial, antifungal and antiviral agents. Of particular interest are peptide dendrimers as a medium for transport of therapeutic substances: synthetic vaccines against parasites, bacteria and viruses, contrast agents used in MRI, antibodies and genetic material. This review focuses on the description of the current classes of dendrimers, the methodology for their synthesis and briefly drawbacks of their properties and their use as potential therapies against infectious diseases.
Asunto(s)
Antiinfecciosos/farmacología , Enfermedades Transmisibles/tratamiento farmacológico , Dendrímeros/química , Péptidos/química , Polímeros/química , Animales , Fármacos Anti-VIH/farmacología , Infecciones Bacterianas/tratamiento farmacológico , Biotecnología , Catálisis , Medios de Contraste , Sistemas de Liberación de Medicamentos , Diseño de Fármacos , Infecciones por VIH/tratamiento farmacológico , Humanos , Infectología/tendencias , Imagen por Resonancia Magnética , Ratones , Nanotecnología , Polipropilenos/química , SARS-CoV-2 , Estereoisomerismo , Tomografía Computarizada por Rayos X/tendencias , Virosis/tratamiento farmacológico , Tratamiento Farmacológico de COVID-19RESUMEN
The Korean government's strategy to combat coronavirus disease 2019 (COVID-19) has focused on non-pharmaceutical interventions, such as social distancing and wearing masks, along with testing, tracing, and treatment; overall, its performance has been relatively good compared to that of many other countries heavily affected by COVID-19. However, little attention has been paid to health equity in measures to control the COVID-19 pandemic. The study aimed to examine the unequal impacts of COVID-19 across socioeconomic groups and to suggest potential solutions to tackle these inequalities. The pathways linking social determinants and health could be entry points to tackle the unequal consequences of this public health emergency. It is crucial for infectious disease policy to consider social determinants of health including poor housing, precarious working conditions, disrupted healthcare services, and suspension of social services. Moreover, the high levels of uncertainty and complexity inherent in this public health emergency, as well as the health and socioeconomic inequalities caused by the pandemic, underscore the need for good governance other than top-down measures by the government. We emphasize that a people-centered perspective is a key approach during the pandemic era. Mutual trust between the state and civil society, strong accountability of the government, and civic participation are essential components of cooperative disaster governance.
Asunto(s)
COVID-19/prevención & control , Equidad en Salud/normas , Política de Salud , Infectología/legislación & jurisprudencia , COVID-19/fisiopatología , Programas de Gobierno/legislación & jurisprudencia , Programas de Gobierno/métodos , Equidad en Salud/estadística & datos numéricos , Humanos , Infectología/métodos , Infectología/tendencias , Pandemias/prevención & control , Pandemias/estadística & datos numéricos , Salud Pública/legislación & jurisprudencia , Salud Pública/métodos , Salud Pública/tendencias , República de CoreaRESUMEN
What's new in infectious diseases in 2020â ? This year has been marked by the COVID-19 pandemic, prompting a review of the current knowledge on SARS-CoV-2 and its management in this article. The results of the Swiss project «â PIRATEâ ¼ indicate non-inferiority between CRP-guided antibiotic durations or fixed 7-day durations and 14-day durations for Gram-negative bacteremia. A Mongolian study did not show any benefit of vitamin D substitution in protecting children from tuberculosis. Baloxavir, a new antiviral against the flu, has been approved by Swissmedic. Finally, new American recommendations for therapeutic monitoring of vancomycin and universal screening for hepatitis C virus have been published.
Que dire des nouveautés en maladies infectieuses en 2020â ? L'année a été marquée évidemment par la pandémie du Covid-19, motivant une revue dans cet article, des connaissances actuelles sur le SARS-CoV-2 et de sa prise en charge. Les résultats du projet suisse PIRATE ont montré une non-infériorité pour les bactériémies Gram négatif entre une antibiothérapie de 7 jours ou guidée par la CRP face à une durée de 14 jours. Une étude mongolienne n'a pas permis de montrer le bénéfice d'une substitution en vitamine D chez les enfants sur l'incidence de la tuberculose. Le baloxavir, un nouvel antiviral contre la grippe, a été approuvé par Swissmedic. Et enfin, des nouvelles recommandations américaines sur le monitoring thérapeutique de la vancomycine et sur le dépistage universel de l'hépatite C ont été publiées.
Asunto(s)
Infectología/tendencias , Antibacterianos/administración & dosificación , Antivirales/uso terapéutico , Proteína C-Reactiva/análisis , COVID-19 , Niño , Enfermedades Transmisibles/tratamiento farmacológico , Humanos , Gripe Humana/tratamiento farmacológico , Pandemias , Tuberculosis/prevención & control , Vitamina D/administración & dosificaciónRESUMEN
This study aimed to evaluate the infectious disease (ID) physician workforce in Korea. We investigated the acquisition of ID physicians from 1992 to 2019 with their current working place in the Health Care System. We defined ID physicians working at general or tertiary-care hospitals as active ID physicians. A total 275 physicians acquired ID as a sub-specialty. Among the 275, 242 were active ID physicians. The density of active ID physicians was 0.47 per 100,000 population. Of all the 17 administrative districts, 11 (64.7%) fell short of 0.47, and 131 medical institutions employed the service of ID physicians. The median number of beds per adult ID physician was 372 (interquartile range, 280-507). It is essential to secure human resources to respond to emerging infectious diseases and perform the inherent work of ID physicians.
Asunto(s)
Infectología/tendencias , Médicos/provisión & distribución , Recursos Humanos , Enfermedades Transmisibles , Atención a la Salud , Femenino , Humanos , Masculino , Medicina , República de Corea , Encuestas y Cuestionarios , Lugar de TrabajoAsunto(s)
Infecciones del Sistema Respiratorio/epidemiología , Virosis/epidemiología , COVID-19/diagnóstico , COVID-19/epidemiología , COVID-19/terapia , Infección Hospitalaria/diagnóstico , Infección Hospitalaria/economía , Infección Hospitalaria/epidemiología , Infección Hospitalaria/terapia , Epidemias , Europa (Continente)/epidemiología , Francia/epidemiología , Hospitalización/economía , Hospitalización/estadística & datos numéricos , Humanos , Infectología/organización & administración , Infectología/normas , Infectología/tendencias , Mortalidad , Vigilancia de la Población , Salud Pública/economía , Infecciones del Sistema Respiratorio/diagnóstico , Infecciones del Sistema Respiratorio/economía , Infecciones del Sistema Respiratorio/terapia , SARS-CoV-2/fisiología , Estaciones del Año , Virosis/diagnóstico , Virosis/economía , Virosis/terapiaAsunto(s)
COVID-19/epidemiología , Pandemias , Investigación Biomédica/organización & administración , Investigación Biomédica/normas , COVID-19/terapia , Defensa Civil/organización & administración , Defensa Civil/normas , Defensa Civil/tendencias , Ensayos Clínicos como Asunto/organización & administración , Ensayos Clínicos como Asunto/normas , Infección Hospitalaria/epidemiología , Infección Hospitalaria/prevención & control , Atención a la Salud/organización & administración , Atención a la Salud/normas , Desarrollo de Medicamentos/organización & administración , Desarrollo de Medicamentos/normas , Europa (Continente)/epidemiología , Francia/epidemiología , Humanos , Infectología/organización & administración , Infectología/normas , Infectología/tendencias , Cooperación Internacional , Administración en Salud Pública/normas , Publicaciones/estadística & datos numéricos , SARS-CoV-2/fisiologíaAsunto(s)
Gastroenterología , Hepacivirus/aislamiento & purificación , Hepatitis C , Gastroenterología/métodos , Gastroenterología/tendencias , Hepatitis C/epidemiología , Hepatitis C/terapia , Hepatitis C/virología , Humanos , Infectología/métodos , Infectología/tendencias , Premio Nobel , Virología/métodos , Virología/tendenciasRESUMEN
BACKGROUND: Many previous studies of Clostridioides difficile infection (CDI) epidemiology have used hospital discharge data codes, which can have limited accuracy. We used a data set of laboratory-confirmed cases of CDI in the province of Manitoba, Canada, to describe the epidemiology of CDI over a decade. METHODS: We conducted a population-based historical cohort study using Manitoba Health's population-wide laboratory-based CDI data set linked to administrative health databases. All individuals living in Manitoba and experiencing a CDI episode between 2005 and 2015 were included (n = 8471) and followed up from CDI diagnosis. We assessed time trends of CDI, incidence and predictors of recurrence and severe outcomes, and health care encounters after CDI diagnosis. CDI episodes were stratified by community versus hospital site of acquiring CDI. RESULTS: Between 2005 and 2009, overall CDI diagnoses decreased by an average of 12.6% per year (95% confidence interval [CI] -4.4 to -20.0), with no statistically significant change from 2010 to 2015. In stratified analysis, incident and recurrent CDI had a similar decrease in the initial study time period and then stabilized. The proportion of community-associated CDI cases increased by an average of 4.8% per year (95% CI 2.8 to 6.8) during the study period. CDI acquired in a health care facility had a higher recurrence rate and more severe outcomes. Recurrence of CDI increased the likelihood of admission to hospital. INTERPRETATION: Between 2005 and 2015, the rates of overall laboratory-confirmed CDI, incident CDI, recurrent CDI and severe outcomes following CDI initially decreased before stabilizing, and an increasing proportion of CDI cases were community-associated. There is an increasing need to test for CDI among outpatients with diarrhea and to increase efforts to prevent recurrent CDI.
Asunto(s)
Clostridioides difficile , Infecciones por Clostridium/epidemiología , Infección Hospitalaria/epidemiología , Anciano , Anciano de 80 o más Años , Infecciones por Clostridium/diagnóstico , Estudios de Cohortes , Bases de Datos Factuales , Femenino , Humanos , Incidencia , Infectología/tendencias , Masculino , Manitoba/epidemiología , Persona de Mediana Edad , Análisis Multivariante , Modelos de Riesgos Proporcionales , RecurrenciaRESUMEN
Infectious diseases as a specialty is tilted toward social justice, and practitioners are frequently on the front lines of the battle against health inequity in practices that are diverse and sometimes cross international borders. Whether caring for patients living with the human immunodeficiency virus, tuberculosis, or Ebola, infectious diseases practitioners often interact with those at the margins of societies (eg, racial/ethnic/sexual/gender minorities), who disproportionately bear the brunt of these conditions. Therefore, cultural barriers between providers and patients are often salient in the infectious diseases context. In this article, we discuss cultural competence broadly, to include not only the knowledge and the skills needed at both the organizational and the individual levels to provide culturally appropriate care, but also to include "cultural humility"-a lifelong process of learning, self-reflection, and self-critique. To enhance the quality and the impact of our practices, we must prioritize cultural competence and humility and be mindful of the role of culture in the patient-provider-system interactions, in our larger healthcare systems, and in our research agendas and workforce development.
Asunto(s)
Investigación Biomédica/normas , Competencia Cultural , Atención a la Salud/normas , Infectología/normas , Actitud del Personal de Salud , Investigación Biomédica/tendencias , Diversidad Cultural , Atención a la Salud/tendencias , Humanos , Infectología/tendencias , Justicia SocialRESUMEN
Mucormycosis are life-threatening fungal infections especially affecting immunocompromised or diabetic patients. Despite treatment, mortality remains high (from 32 to 70% according to organ involvement). This review provides an update on mucormycosis management. The latest recommendations strongly recommend as first-line therapy the use of liposomal amphotericin B (≥5mg/kg) combined with surgery whenever possible. Isavuconazole and intravenous or delayed-release tablet forms of posaconazole have remained second-line. Many molecules are currently in development to fight against invasive fungal diseases but few have demonstrated efficacy against Mucorales. Despite in vitro efficacy, combinations of treatment have failed to demonstrate superiority versus monotherapy. Adjuvant therapies are particularly complex to evaluate without prospective randomized controlled studies, which are complex to perform due to low incidence rate and high mortality of mucormycosis. Perspectives are nonetheless encouraging. New approaches assessing relationships between host, fungi, and antifungal drugs, and new routes of administration such as aerosols could improve mucormycosis treatment.
Asunto(s)
Infectología/normas , Infectología/tendencias , Mucormicosis/terapia , Guías de Práctica Clínica como Asunto , Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Terapia Combinada/métodos , Terapia Combinada/normas , Terapia Combinada/tendencias , Complicaciones de la Diabetes/microbiología , Humanos , Huésped Inmunocomprometido , Infectología/métodos , Procedimientos Quirúrgicos Operativos/métodos , Procedimientos Quirúrgicos Operativos/normas , Procedimientos Quirúrgicos Operativos/tendencias , Terapias en Investigación/métodos , Terapias en Investigación/tendenciasRESUMEN
Transmission of infectious diseases between immobile hosts (e.g., plants, farms) is strongly dependent on the spatial distribution of hosts and the distance-dependent probability of transmission. As the interplay between these factors is poorly understood, we use spatial process and transmission modelling to investigate how epidemic size is shaped by host clustering and spatial range of transmission. We find that for a given degree of clustering and individual-level infectivity, the probability that an epidemic occurs after an introduction is generally higher if transmission is predominantly local. However, local transmission also impedes transfer of the infection to new clusters. A consequence is that the total number of infections is maximal if the range of transmission is intermediate. In highly clustered populations, the infection dynamics is strongly determined by the probability of transmission between clusters of hosts, whereby local clusters act as multiplier of infection. We show that in such populations, a metapopulation model sometimes provides a good approximation of the total epidemic size, using probabilities of local extinction, the final size of infections in local clusters, and probabilities of cluster-to-cluster transmission. As a real-world example we analyse the case of avian influenza transmission between poultry farms in the Netherlands.
Asunto(s)
Brotes de Enfermedades , Transmisión de Enfermedad Infecciosa , Infectología/tendencias , Algoritmos , Crianza de Animales Domésticos , Animales , Análisis por Conglomerados , Granjas , Infectología/métodos , Gripe Aviar/epidemiología , Gripe Aviar/transmisión , Modelos Biológicos , Países Bajos , Distribución Normal , Dinámica Poblacional , Aves de Corral , Probabilidad , Modelos de Riesgos Proporcionales , RiesgoRESUMEN
BACKGROUND: In the early phase of the COVID-19 pandemic Germany missed to set up efficient containment measures. Consequently, the number of cases increased exponentially until a lockdown was implemented to suppress the spread of SARS-CoV-2. Fortunately, Germany has a high capability for coronavirus lab testing and more than 30,000 ICU beds. These capabilities and the lockdown turned out to be an advantage to combat the pandemic and to prevent a health-system overload. AIM: The aim was to predict the plateau day of SARS-CoV-2 infections or deaths. RESULTS: The effect on the viral spread of the German measures taken and the impact on the peak of new infection cases is shown. By normalizing daily case numbers, the plateau day of the current outbreak in Germany could be calculated to be reached at April 12, 2020 (day 103 of 2020). CONCLUSION: Normalized case number curves are helpful to predict the time point at which no further new infections will occur if the epidemic situation remains stable. Upon reaching the plateau day during a lockdown phase, a residual time-period of about 2-3 weeks can be utilized to prepare a safe unlocking period. As can be learned from Asian countries such as South Korea and Taiwan there must be strict rules to keep the risk of infection low. Those include social distancing, face mask wearing in combination with digital contact tracing and serosurveillance studies. Following those rules, a safe dance around the infection curve allows to keep the population at a reduced infection rate.
Asunto(s)
Control de Enfermedades Transmisibles/métodos , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Betacoronavirus , COVID-19 , China/epidemiología , Infecciones por Coronavirus/prevención & control , Brotes de Enfermedades , Alemania/epidemiología , Humanos , Infectología/tendencias , Unidades de Cuidados Intensivos , Modelos Lineales , Pandemias/prevención & control , Neumonía Viral/prevención & control , Cuarentena , SARS-CoV-2 , Organización Mundial de la SaludRESUMEN
Tuberculosis is the infectious disease that causes the most deaths each year in the world. Around 25% of the population is estimated to be infected with, Mycobacterium tuberculosis, the bacteria that gives rise to the disease, and more than one and a half million people die each year from this cause. A rigorous bibliometric analysis has been developed around tuberculosis disease, and the most remarkable results are presented in this paper. It is observed that interest in tuberculosis is growing, and the control of its spread has become one of the main health priorities in the world, with the United States, the United Kingdom, and India, leading the research in this area. On the other hand, it has been observed that there are two main health concerns around the tuberculosis: drug-resistant tuberculosis and co-infection with HIV. Finally, conclusions are offered, playing a frontline role in science policy decisions and research performance evaluations.
Asunto(s)
Bacteriología/tendencias , Investigación Biomédica/tendencias , Salud Global/tendencias , Infectología/tendencias , Proyectos de Investigación/tendencias , Tuberculosis , Antituberculosos/uso terapéutico , Bibliometría , Coinfección , Difusión de Innovaciones , Farmacorresistencia Bacteriana , Predicción , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Humanos , Factores de Tiempo , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Tuberculosis/microbiologíaAsunto(s)
Síndrome de Inmunodeficiencia Adquirida , Infectología/organización & administración , Infectología/tendencias , Medicina Tropical/organización & administración , Medicina Tropical/tendencias , Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Síndrome de Inmunodeficiencia Adquirida/terapia , Redes Comunitarias/organización & administración , Redes Comunitarias/tendencias , Congresos como Asunto , Países en Desarrollo , VIH , Humanos , Cooperación Internacional , Senegal , Terapias en Investigación/métodos , Terapias en Investigación/tendenciasRESUMEN
On our 15th anniversary, the PLOS Medicine editors discuss progress in open access, medical publishing and the journal's mission over the years.